A single sub-psychotomimetic dose of ketamine, an ionotropic glutamatergic n-methyl-d-aspartate (NMDA) receptor antagonist, produces a fast-acting antidepressant response in patients suffering from major depressive disorder. Depressed patients report alleviation of core symptoms within two hours of a single low-dose intravenous infusion of ketamine with effects lasting up to two weeks. The rapidity of ketamine action implies that major symptoms of depression can be alleviated without substantial structural plasticity or circuit rewiring. Therefore, the ability of ketamine to exert a rapid effect provides a unique opportunity to elucidate the types of acute synaptic plasticity changes that can be recruited to counter depression symptoms.
Popular Blog Posts
End The Stigma!
Lady Gaga and Bradley Cooper did a masterful remake of “A Star is Born”, now in theaters. We highly…
Dr. Sanjay Gupta on CNN: “Ketamine offers lifeline for people with severe depression, suicidal thoughts”
In this post, a Wisconsin man who had been on the brink of suicide, told CNN’s Sanjay Gupta how…
The Resurgence of Psychedelics in Medicine
There has been a flurry of articles in the media recently touting the successful use of psychedelics in medicine.…
Ketamine Infusions Provide Effective Relief for Severe Chronic Headache
Medical research is revealing more and more applications for ketamine, the old drug being used in new ways. Just…
New Insight Into How Ketamine Works in Depression
Ketamine exerts an initial antidepressant effect by blocking the N-methyl-D-aspartate receptor (NMDAR), and the ketamine metabolite hydroxynorketamine (HNK) may extend…